The latest market price of Crizotinib in 2025

Crizotinib is a multi-target tyrosine kinase inhibitor that mainly targets ALK, ROS1 and MET pathways. The indications currently approved in China include ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), and ROS1-positive advanced non-small cell lung cancer. These patients are often diagnosed through genetic testing and subsequently treated with crizotinib, which significantly improves progression-free survival and response rates.

In terms of price, the original drug crizotinib has been on the domestic market for many years. The packaging specifications are usually 250 mg 60 pills or 200 mg 60 pills. The price of each box may exceed RMB 10,000. Considering that lung cancer patients often require long-term continuous medication, this price is still a heavy burden for many families. Fortunately, however, crizotinib has been included in the national medical insurance catalog, and eligible patients can receive medical insurance reimbursement, significantly reducing actual out-of-pocket expenditures.

In overseas markets, the price of crizotinib is also relatively high, around RMB 10,000 per box, and the price fluctuates due to exchange rates. However, as patents expire and generic drugs are launched, prices in some countries have dropped significantly. Especially the generic drugs from India, Bangladesh, and Laos have the same ingredients as the original drugs, and the specifications are mostly 250mg*60 pills. The price per box is about 2,000 yuan, which is significantly lower than the original drugs. This gap has driven some patients to seek more cost-effective medication solutions through formal overseas channels.

In general, crizotinib is an important targeted drug in the field of non-small cell lung cancer, with clear indications and widely recognized clinical efficacy. Although the price is higher, with the gradual advancement of medical insurance coverage and generic drugs, the financial burden on patients is gradually being reduced. In the future, as more domestic versions are launched, the market price is expected to drop further, allowing more ALK or ROS1-positive patients to benefit.

Reference materials:https://go.drugbank.com/drugs/DB08865